Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 12/2013

01.12.2013 | Infection (J Berger, Section Editor)

Update on Herpes Virus Infections of the Nervous System

verfasst von: Israel Steiner, Felix Benninger

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 12/2013

Einloggen, um Zugang zu erhalten

Abstract

Herpes simplex viruses types 1 and 2 (HSV-1 and HSV-2) are human neurotropic viruses that establish latent infection in dorsal root ganglia (DRG) for the entire life of the host. From the DRG they can reactivate to cause human morbidity and mortality. Although they vary, in part, in the clinical disorders they cause, and in their molecular structure, they share several features that govern the biology of their infection of the human nervous system. HSV-1 is the causative agent of encephalitis, corneal blindness, and several peripheral nervous system disorders; HSV-2 is responsible for meningoencephalitis in neonates and meningitis in adults. The biology of their ability to establish latency, maintain it for the entire life of the host, reactivate, and cause primary and recurrent disease is being studied in animal models and in humans. This review covers recent advances in understanding the biology and pathogenesis of HSV-related disease.
Literatur
1.
Gilden DH, Mahalingam R, Cohrs RJ, Tyler KL. Herpesvirus infections of the nervous system. Nat Clin Pract Neurol. 2007;3:82–94.PubMedCrossRef
2.
Dolan A, Jamieson FE, Cunningham C. The genome sequence of herpes simplex virus type 2. J Virol. 1998;72:2010–21.PubMed
3.
McGeoch DJ, Dolan A, Donald S, Brauer DHK. Complete DNA sequence of the short repeat region in the genome of herpes simplex virus type 1. Nucl Acids Res. 1986;14:1727–45.PubMedCrossRef
4.
McGeoch DJ. The genomes of the human herpesviruses: contents, relationships, and evolution. Annu Rev Microbiol. 1989;43:235–65.PubMedCrossRef
5.
• Egan KP, Wu S, Wigdahl B, Jennings SR. Immunological control of herpes simplex virus infections. J Neurovirol. 2013;19:328–45. Comprehensive description of immune mechanisms involved in latency and virus control.PubMedCrossRef
6.
Kennedy PGE, Chaudhuri A. Herpes simplex encephalitis. J Neurol Neurosurg Psychiatry. 2002;73:237–38.PubMedCrossRef
7.
Steiner I. Herpes simplex virus meningoencephalitis. In: Jackson AC, editor. Viral infections of the human nervous system. Birkhäuser advances in infectious diseases. Basel: Springer; 2013. pp. 47–63.
8.
Abaitua F, Zia R, Hollinshead M, O'Hare P. Polarised cell migration during cell-to-cell transmission of herpes simplex virus in human skin keratinocytes. J Virol. 2013;87:7921–32.PubMedCrossRef
9.
Lee JI, Sollars PJ, Baver SB, Pickard GE. A herpesvirus encoded deubiquitinase is a novel neuroinvasive determinant. PLoS Pathogens. 2009;5:e1000387.PubMedCrossRef
10.
Böttcher S, Maresch C, Granzow H, Klupp BG, Teifke JP, Mettenleiter TC. Mutagenesis of the active-site cysteine in the ubiquitin-specific protease contained in large tegument protein pUL36 of pseudorabies virus impairs viral replication in vitro and neuroinvasion in vivo. J Virol. 2008;82:6009–16.PubMedCrossRef
11.
Antinone SE, Smith GA. Retrograde axon transport of herpes simplex virus and pseudorabies virus: a live-cell comparative analysis. J Virol. 2010;84:1504–12.PubMedCrossRef
12.
Feierbach B, Bisher M, Goodhouse J, Enquist LW. In Vitro analysis of transneuronal spread of an alphaherpesvirus infection in peripheral nervous system neurons. J Virol. 2007;81:6846–57.PubMedCrossRef
13.
Granstedt AE, Brunton BW, Enquist LW. (2013) Imaging the transport dynamics of single alphaherpesvirus particles in intact peripheral nervous system explants from infected mice. mBio 4: e00358–13–e00358–13.
14.
Bertke AS, Apakupakul K, Ma A, Imai Y, Gussow AM, Wang K, et al. LAT region factors mediating differential neuronal tropism of HSV-1 and HSV-2 do not act in trans. PLoS One. 2012;7:e53281.PubMedCrossRef
15.
Bloom DC, Kwiatkowski DL. HSV-1 latency and the roles of the LATs. In Weller (ed.) Alphaherpesviruses: molecular virology. Caister Academic Press; 2011, pp. 286–312.
16.
Bertke AS, Swanson SM, Chen J, Imai Y, Kinchington PR, Margolis TP. A5-positive primary sensory neurons are nonpermissive for productive infection with herpes simplex virus 1 in vitro. J Virol. 2011;85:6669–77.PubMedCrossRef
17.
Knipe DM, Cliffe A. Chromatin control of herpes simplex virus lytic and latent infection. Nat Rev Micro. 2008;6:211–21.CrossRef
18.
Bloom DC, Giordani NV, Kwiatkowski DL. Epigenetic regulation of latent HSV-1 gene expression. Biochim Biophys Acta. 2010;1799:246–56.PubMedCrossRef
19.
Su Y-H, Moxley MJ, Ng AK, Lin J, Jordan R, Fraser NW, et al. Stability and circularization of herpes simplex virus type 1 genomes in quiescently infected PC12 cultures. J Gen Virol. 2002;83:2943–50.PubMed
20.
Steiner I, Spivack JG, O'Boyle DR, Lavi E, Fraser NW. Latent herpes simplex virus type 1 transcription in human trigeminal ganglia. J Virol. 1988;62:3493–6.PubMed
21.
Stevens JG, Wagner EK, Devi-Rao GB, Cook ML, Feldman LT. RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science. 1987;235:1056–9.PubMedCrossRef
22.
Trousdale MD, Steiner I, Spivack JG, Deshmane SL, Brown SM, MacLean AR, et al. In vivo and in vitro reactivation impairment of a herpes simplex virus type 1 latency-associated transcript variant in a rabbit eye model. J Virol. 1991;65:6989–93.PubMed
23.
Steiner I, Spivack JG, Lirette RP, Brown SM, MacLean AR, Subak-Sharpe JH, et al. Herpes simplex virus type 1 latency-associated transcripts are evidently not essential for latent infection. EMBO J. 1989;8:505–11.PubMed
24.
Carpenter D, Hsiang C, Brown DJ, Jin L, Osorio N, BenMohamed L, et al. Stable cell lines expressing high levels of the herpes simplex virus type 1 LAT are refractory to caspase 3 activation and DNA laddering following cold shock induced apoptosis. Virology. 2007;369:12–8.PubMedCrossRef
25.
Branco FJ, Fraser NW. Herpes simplex virus type 1 latency-associated transcript expression protects trigeminal ganglion neurons from apoptosis. J Virol. 2005;79:9019–25.PubMedCrossRef
26.
Perng G-C, Jones C. Towards an understanding of the herpes simplex virus type 1 latency-reactivation cycle. In Solbrig (ed.) Interdisciplinary perspectives on infectious diseases. Hindawi Publishing Corporation;2010, pp. 1–18.
27.
Jurak I, Silverstein LB, Sharma M, Coen DM. Herpes simplex virus is equipped with RNA-and protein-based mechanisms to repress expression of ATRX, an effector of intrinsic immunity. J Virol. 2012;86:10093–102.PubMedCrossRef
28.
•• Nicoll MP, Proença JT, Efstathiou S. The molecular basis of herpes simplex virus latency. FEMS Microbiol Rev. 2012;36:684–705. Latest experimental research on the control of herpes virus latency in neurons.PubMedCrossRef
29.
Held K, Derfuss T. Control of HSV-1 latency in human trigeminal ganglia—current overview. J Neurovirol. 2011;17:518–27.PubMedCrossRef
30.
Goldenberg D, Mador N, Ball MJ, Panet A, Steiner I. The abundant latency-associated transcripts of herpes simplex virus type 1 are bound to polyribosomes in cultured neuronal cells and during latent infection in mouse trigeminal ganglia. J Virol. 1997;71:2897–904.PubMed
31.
Feldman LT. Spontaneous molecular reactivation of herpes simplex virus type 1 latency in mice. Proc Natl Acad Sci U S A. 2002;99:978–83.PubMedCrossRef
32.
Wysocka J, Herr W. The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. Trends Biochem Sci. 2003;28:294–304.PubMedCrossRef
33.
Thompson RL, Preston CM, Sawtell NM. De novo synthesis of VP16 coordinates the exit from HSV latency in vivo. PLoS Pathogens. 2009;5:e1000352.PubMedCrossRef
34.
Huang J, Lazear HM, Friedman HM. Completely assembled virus particles detected by transmission electron microscopy in proximal and mid-axons of neurons infected with herpes simplex virus type 1, herpes simplex virus type 2 and pseudorabies virus. Virology. 2011;409:12–6.PubMedCrossRef
35.
Wisner TW, Sugimoto K, Howard PW, Kawaguchi Y, Johnson DC. Anterograde transport of herpes simplex virus capsids in neurons by both separate and married mechanisms. J Virol. 2011;85:5919–28.PubMedCrossRef
36.
Karasneh GA, Shukla D. Herpes simplex virus infects most cell types in vitro: clues to its success. Virol J. 2011;8:481.PubMedCrossRef
37.
38.
• Steiner I. Herpes simplex virus encephalitis: new infection or reactivation? Curr Opin Neurol. 2011;24:268–74. Discussion about the etiology of herpes encephalitis and if to consider a primary injection or reactivation.PubMedCrossRef
39.
Solomon T, Michael B, Smith P, Sanderson F. Management of suspected viral encephalitis in adults–Association of British Neurologists and British Infection Association National Guidelines. J Infect. 2012;64:347–73.PubMedCrossRef
40.
Whitley RJ, Alford CA, Hirsch MS, Schooley RT, Luby JP, Aoki FY, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med. 1986;314:144–9.PubMedCrossRef
41.
42.
Kennedy PGE, Steiner I. Recent issues in herpes simplex encephalitis. J Neurovirol. 2013;19:346–50.PubMedCrossRef
43.
Landau Z, Miller E, Roif M. Recurrent herpes simplex encephalitis. Eur J Int Med. 2005;16:513–14.CrossRef
44.
Yamada S, Kameyama T, Nagaya S, Hashizume Y, Yoshida M. Relapsing herpes simplex encephalitis: pathological confirmation of viral reactivation. J Neurol Neurosurg Psychiatry. 2003;74:262–4.PubMedCrossRef
45.
Whitley RJ. Herpes simplex virus. In: Sheld, Whitley, and Marra (eds.) Infections of the central nervous system. Lippincott Williams & Wilkins; 2004, pp. 123–44.
46.
47.
Baskin HJ, Hedlund G. Neuroimaging of herpesvirus infections in children. Pediatr Radiol. 2007;37:949–63.PubMedCrossRef
48.
Castillo M, Rumboldt Z. Herpes simplex encephalitis. In Rumboldt et al. (ed.) Brain imaging with MRI and CT: an image pattern approach. Cambridge University Press, New York 2012, pp. 41–2
49.
Esiri MM. Herpes simplex encephalitis: an immunohistological study of the distribution of viral antigen within the brain. J Neurol Sci. 1982;54:209–26.PubMedCrossRef
50.
Tissari J, Sirén J, Meri S, Julkunen I, Matikainen S. IFN-α enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol. 2005;174:4289–94.PubMed
51.
•• Okun E, Griffioen KJ, Mattson MP. Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci. 2011;34:269–81. Very comprehensive summary of Toll-like receptor functions.PubMedCrossRef
52.
Okun E, Griffioen KJ, Lathia JD, Tang SC. Toll-like receptors in neurodegeneration. Brain Res. 2009;59:278–92.CrossRef
53.
Guo Y, Audry M, Ciancanelli M, Alsina L, Azevedo J, Herman M, et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J Exp Med. 2011;208:2083–98.PubMedCrossRef
54.
Sancho-Shimizu V, deDiego RP, Lorenzo L, Halwani R, et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J Clin Invest. 2011;121:4889.PubMedCrossRef
55.
Herman M, Ciancanelli M, Ou YH, Lorenzo L, Klaudel-Dreszler M, Pauwels E, et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J Exp Med. 2012;209:1567–82.PubMedCrossRef
56.
Zhang S-Y, Jouanguy E, Ugolini S, Smahi A, Elain G, Romero P, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science. 2007;317:1522–7.PubMedCrossRef
57.
Leib DA. Herpes simplex virus encephalitis: Toll-free access to the brain. Cell Host Microbe. 2012;12:731–2.PubMedCrossRef
58.
Lafaille FG, Pessach IM, Zhang S-Y, Ciancanelli MJ, Herman M, Abhyankar A, et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature. 2012;491:769–73.PubMed
59.
Zhang S-Y, Herman M, Ciancanelli MJ, de Diego RP, Sancho-Shimizu V, Abel L, et al. TLR3 immunity to infection in mice and humans. Curr Opin Immunol. 2013;25:19–33.PubMedCrossRef
60.
Perales-Linares R, Navas-Martin S. Toll-like receptor 3 in viral pathogenesis: friend or foe? Immunology. 2013;140:153–67.PubMedCrossRef
61.
Voskoboinik I, Smyth MJ, Trapani JA. Perforin-mediated target-cell death and immune homeostasis. Nat Rev Immunol. 2006;6:940–52.PubMedCrossRef
62.
Smyth MJ, Trapani JA. Granzymes: exogenous porteinases that induce target cell apoptosis. Immunol Today. 1995;16:202–6.PubMedCrossRef
63.
64.
Joly E, Mucke L, Oldstone M. Viral persistence in neurons explained by lack of major histocompatibility class I expression. Science. 1991;253:1283–5.PubMedCrossRef
65.
Oldstone MB. Molecular anatomy of viral persistence. J Virol. 1991;65:6381.PubMed
66.
Knickelbein JE, Hendricks RL, Charukamnoetkanok P. Management of herpes simplex virus stromal keratitis: an evidence-based review. Survey Ophthalmol. 2009;54:226–34.CrossRef
67.
Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, et al. The role of virus-specific Cd8+ cells in liver damage and viral control during persistent hepatitis b virus infection. J Exp Med. 2000;191:1269–80.PubMedCrossRef
68.
Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence. Hepatology. 1999;30:595–601.PubMedCrossRef
69.
Steiner I, Budka H, Chaudhuri A, Koskiniemi M, Sainio K, Salonen O, et al. Viral meningoencephalitis: a review of diagnostic methods and guidelines for management. Eur J Neurol. 2010;17:999–e57.PubMedCrossRef
70.
Cinque P, Cleator GM, Weber T, Monteyne P, Sindic CJ, van Loon AM. The role of laboratory investigation in the diagnosis and management of patients with suspected herpes simplex encephalitis: a consensus report. The EU Concerted Action on Virus Meningitis and Encephalitis. J Neurol Neurosurg Psychiatry. 1996;61:339–45.PubMedCrossRef
71.
Benninger F, Steiner I. Steroids in bacterial meningitis: yes. J Neural Transm. 2013;120:339–42.PubMedCrossRef
72.
Quagliarello V, Scheld WM. Infectious disease: do steroids benefit patients with bacterial meningitis? Nat Rev Neurol. 2010;:529–30.
73.
Jacobs DH. Herpes simplex virus encephalitis following corticosteroids and cranial irradiation. Neurology. 1999;52:1106.CrossRef
74.
Thompson KA, Blessing WW, Wesselingh SL. Herpes simplex replication and dissemination is not increased by corticosteroid treatment in a rat model of focal Herpes encephalitis. J Neurovirol. 2000;6:25–32.PubMedCrossRef
75.
Meyding-Lamadé UK, Oberlinner C, Rau PR. Experimental herpes simplex virus encephalitis: a combination therapy of acyclovir and glucocorticoids reduces long-term magnetic resonance imaging abnormalities. J Neurovirol. 2003;9:118–25.PubMed
76.
Almalki DM, Al-Suwaidan FB. Steroid pulse therapy in herpes simplex encephalitis. Neurosciences (Riyadh). 2013;18:276–7.PubMed
77.
Kamei S. Evaluation of combination therapy using aciclovir and corticosteroid in adult patients with herpes simplex virus encephalitis. J Neurol Neurosurg Psychiatry. 2005;76:1544–9.PubMedCrossRef
78.
Lizarraga KJ, Alexandre LC, Ramos-Estebanez C, Merenda A. Are steroids a beneficial adjunctive therapy in the immunosuppressed patient with herpes simplex virus encephalitis? Case Rep Neurol. 2013;5:52–5.PubMedCrossRef
79.
• Martinez-Torres F, Menon S, Pritsch M, Victor N, Jenetzky E, Jensen K, et al. German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial. BMC Neurol. 2008;8:40. Initial description of the GACHE trial; still awaiting results.PubMedCrossRef
80.
VanLandingham KE, Marsteller HB. Relapse of herpes simplex encephalitis after conventional acyclovir therapy. JAMA. 1988;259:1051–3.PubMedCrossRef
81.
Ito Y, Kimura H, Yabuta Y, Ando Y. Exacerbation of herpes simplex encephalitis after successful treatment with acyclovir. Clin Infect Dis. 2000;30:185–7.PubMedCrossRef
82.
Kimura H, Aso K, Kuzushima K, Hanada N. Relapse of herpes simplex encephalitis in children. Pediatrics. 1992;89:891–4.PubMed
83.
Sköldenberg B, Aurelius E, Hjalmarsson A, Sabri F. Incidence and pathogenesis of clinical relapse after herpes simplex encephalitis in adults. J Neurol. 2006;253:163–70.PubMedCrossRef
84.
Barthez-Carpentier MA, Rozenberg F. Relapse of herpes simplex encephalitis. J Child Neurol. 1995;10:363–8.PubMedCrossRef
85.
Gable MS, Sheriff H, Dalmau J. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California. Clin Infect Dis. 2012;54:899–904.PubMedCrossRef
86.
Armangue T, Titulaer MJ, Málaga I, Bataller L. Pediatric anti-N-methyl-D-aspartate receptor encephalitis—clinical analysis and novel findings in a series of 20 patients. J Pediatr. 2013;162:850–6.PubMedCrossRef
87.
Berger JR, Houff S. Neurological complications of herpes simplex virus type 2 infection. Arch Neurol. 2008;65:596–600.PubMedCrossRef
88.
89.
Thompson C, Whitley R. Neonatal herpes simplex virus infections: where are we now? Adv Exp Med Biol. 2011;697:221–30.PubMedCrossRef
90.
James SH, Kimberlin DW, Whitley RJ. Antiviral therapy for herpesvirus central nervous system infections: Neonatal herpes simplex virus infection, herpes simplex encephalitis, and congenital cytomegalovirus infection. Antiviral Res. 2009;83:207–13.PubMedCrossRef
91.
92.
Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347:1652–61.PubMedCrossRef
93.
Belshe RB, Leone PA, Bernstein DI. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med. 2012;366:34–43.PubMedCrossRef
Metadaten
Titel
Update on Herpes Virus Infections of the Nervous System
verfasst von
Israel Steiner
Felix Benninger
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 12/2013
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-013-0414-8

Weitere Artikel der Ausgabe 12/2013

Current Neurology and Neuroscience Reports 12/2013 Zur Ausgabe

Neuro-Ophthalmology (A Kawasaki, Section Editor)

Neuro-ophthalmologic Complications of Neoplastic Leptomeningeal Disease

Movement Disorders (SA Factor, Section Editor)

Genetics in Dystonia: An Update

Demyelinating Disorders (DN Bourdette and V Yadav, Section Editors)

Misdiagnosis of Multiple Sclerosis: Frequency, Causes, Effects, and Prevention

Neuro-Ophthalmology (A Kawasaki, Section Editor)

Posterior Cortical Atrophy: Review of the Recent Literature

Neuroimaging (DJ Brooks, Section Editor)

Imaging of Neuroinflammation in Parkinsonian Syndromes with Positron Emission Tomography

Dementia (K Marder, Section Editor)

Chronic Traumatic Encephalopathy: Where Are We and Where Are We Going?

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise